Medicare's surprise look at AMD (age-related macular degeneration) clinical outcomes
This article was originally published in Clinica
Executive Summary
Going beyond its usual role, the Medicare coverage advisory committee (MCAC) weighed in this week on the best clinical outcomes to use when studying new treatments for age-related macular degeneration (AMD), the most common cause of blindness in the elderly.